552 related articles for article (PubMed ID: 15763239)
1. Cellular electrophysiological effect of terikalant in the dog heart.
Biliczki P; Acsai K; Virág L; Tálosi L; Jost N; Biliczki A; Papp JG; Varró A
Eur J Pharmacol; 2005 Mar; 510(3):161-6. PubMed ID: 15763239
[TBL] [Abstract][Full Text] [Related]
2. Electrophysiological effects of ACC-9358, a novel class I antiarrhythmic agent, on isolated canine Purkinje fibers and ventricular muscle.
Brown BS
J Pharmacol Exp Ther; 1989 Feb; 248(2):552-8. PubMed ID: 2918472
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the electrophysiological effects of ambasilide, a new antiarrhythmic agent, in canine isolated ventricular muscle and purkinje fibers.
Baláti B; Iost N; Simon J; Varró A; Papp JG
Gen Pharmacol; 2000 Feb; 34(2):85-93. PubMed ID: 10974415
[TBL] [Abstract][Full Text] [Related]
4. Terikalant modifies the contractility and effective refractory period of heart muscle: comparative study in rats and guinea pigs.
Kocić I
Pol J Pharmacol; 1998; 50(4-5):327-31. PubMed ID: 10091717
[TBL] [Abstract][Full Text] [Related]
5. Actions of the benzopyran compound terikalant on macroscopic currents in rat ventricular myocytes.
McLarnon JG; Xu R
J Pharmacol Exp Ther; 1995 Oct; 275(1):389-96. PubMed ID: 7562576
[TBL] [Abstract][Full Text] [Related]
6. Diverse electrophysiologic effects of propafenone and flecainide in canine Purkinje fibers: implications for antiarrhythmic drug classification.
Zaza A; Malfatto G; Schwartz PJ
J Pharmacol Exp Ther; 1994 Apr; 269(1):336-43. PubMed ID: 8169840
[TBL] [Abstract][Full Text] [Related]
7. RP 58866 and its active enantiomer RP 62719 (terikalant): blockers of the inward rectifier K+ current acting as pure class III antiarrhythmic agents.
Escande D; Mestre M; Cavero I; Brugada J; Kirchhof C
J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S106-13. PubMed ID: 1279302
[TBL] [Abstract][Full Text] [Related]
8. The role of the delayed rectifier component IKs in dog ventricular muscle and Purkinje fibre repolarization.
Varro A; Baláti B; Iost N; Takács J; Virág L; Lathrop DA; Csaba L; Tálosi L; Papp JG
J Physiol; 2000 Feb; 523 Pt 1(Pt 1):67-81. PubMed ID: 10675203
[TBL] [Abstract][Full Text] [Related]
9. [The mechanism of antiarrhythmic action of 7-bromoethoxybenzene-tetrahydropalmatine].
Yang BF; Zong XG; Wang G; Yao WX; Jiang MX
Yao Xue Xue Bao; 1990; 25(7):481-4. PubMed ID: 2085121
[TBL] [Abstract][Full Text] [Related]
10. Frequency and voltage-dependent effects of mono-N-dealkyldisopyramide, the major metabolite of disopyramide, in canine ventricular tissue.
Toy W; Sasyniuk BI
J Pharmacol Exp Ther; 1990 Aug; 254(2):603-11. PubMed ID: 2166798
[TBL] [Abstract][Full Text] [Related]
11. Electrophysiological effects of EGIS-7229, a new antiarrhythmic agent, in isolated mammalian and human cardiac tissues.
Pankucsi C; Bányász T; Magyar J; Gyönös I; Kovács A; Varró A; Szénási G; Nánási PP
Naunyn Schmiedebergs Arch Pharmacol; 1997 Mar; 355(3):398-405. PubMed ID: 9089672
[TBL] [Abstract][Full Text] [Related]
12. Electrophysiological effects of the new antiarrhythmic drug 3-(diisopropylaminoethylamino)-2',6'-dimethylpropionanilide++ + on dog cardiac muscle.
Sato Y; Iijima T; Taira N
Arzneimittelforschung; 1989 Jan; 39(1):56-9. PubMed ID: 2719743
[TBL] [Abstract][Full Text] [Related]
13. Electrophysiological effects of haloperidol on isolated rabbit Purkinje fibers and guinea pigs papillary muscles under normal and simulated ischemia.
Yan D; Cheng LF; Song HY; Turdi S; Kerram P
Acta Pharmacol Sin; 2007 Aug; 28(8):1155-60. PubMed ID: 17640477
[TBL] [Abstract][Full Text] [Related]
14. Class I/B antiarrhythmic property of ranolazine, a novel antianginal agent, in dog and human cardiac preparations.
Szél T; Koncz I; Jost N; Baczkó I; Husti Z; Virág L; Bussek A; Wettwer E; Ravens U; Papp JG; Varró A
Eur J Pharmacol; 2011 Jul; 662(1-3):31-9. PubMed ID: 21550338
[TBL] [Abstract][Full Text] [Related]
15. Inotropic and electrophysiological effects of AB--2, a new antiarrhythmic agent, on isolated cardiac preparations.
Beresewicz A; Pytkowski B; Sedek G; Zdanowski K
Pol J Pharmacol Pharm; 1983; 35(3):223-32. PubMed ID: 6651921
[TBL] [Abstract][Full Text] [Related]
16. Effects of the potassium channel activator, BRL 34915, on the action potential characteristics of canine cardiac Purkinje fibers.
Bril A; Man RY
J Pharmacol Exp Ther; 1990 Jun; 253(3):1090-6. PubMed ID: 2359018
[TBL] [Abstract][Full Text] [Related]
17. The cellular electropharmacology of mexiletine combined with sotalol in porcine papillary muscle and Purkinje fibre. II. Effects on action potential duration and refractoriness.
Berman ND; Wang LY; Ahmed A
Can J Cardiol; 1990 Nov; 6(9):423-30. PubMed ID: 2177360
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological block of the slow component of the outward delayed rectifier current (I(Ks)) fails to lengthen rabbit ventricular muscle QT(c) and action potential duration.
Lengyel C; Iost N; Virág L; Varró A; Lathrop DA; Papp JG
Br J Pharmacol; 2001 Jan; 132(1):101-10. PubMed ID: 11156566
[TBL] [Abstract][Full Text] [Related]
19. Electrophysiological characterization of BRL-32872 in canine Purkinje fiber and ventricular muscle. Effect on early after-depolarizations and repolarization dispersion.
Faivre JF; Forest MC; Gout B; Bril A
Eur J Pharmacol; 1999 Oct; 383(2):215-22. PubMed ID: 10585537
[TBL] [Abstract][Full Text] [Related]
20. Frequency-dependent and independent effects of tetrodotoxin on Vmax in cardiac fibers.
Varró A; Nakaya Y; Elharrar V; Surawicz B
Acta Physiol Hung; 1989; 73(1):47-52. PubMed ID: 2711842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
